Not unchanged, not unworthy: the disciplined conclusion

Donor human milk banking answers a real clinical need by turning surplus human milk into a controlled product for infants who may not be able to receive enough mother’s own milk. The final question is what “safer” means when the same pathway can reduce microbial hazards, alter heat-sensitive biology, protect or strain donor supply, and produce evidence that is stronger for some claims than for others. The most defensible judgment is that safer donor milk is not biologically unchanged—but biological change does not by itself make the product unsafe, clinically inferior or unworthy.

That conclusion matters because two simple stories are both misleading. One story treats processing as a loss of everything valuable in human milk. The other treats safety as a single switch that, once turned on, settles every question about quality. Donor human milk banking is more demanding than either story. It has to protect a vulnerable recipient, preserve the donor’s own infant’s access to milk, maintain a reliable supply, and retain as much biological function as the evidence and the operating environment allow.

The answer: safety changes milk without erasing its value

The pathway begins with a priority, not a machine. WHO recommends donor human milk for preterm and low-birthweight infants when mother’s own milk is unavailable, in settings where safe and affordable milk-banking facilities are available. Donor milk can serve as a bridge while a mother initiates or restores lactation. This makes donor human milk a specific intervention within a breastfeeding-priority system, not a universal replacement for mother’s own milk and not a reason to weaken support for breastfeeding.

That purpose determines what a successful bank must preserve. It must preserve a safe route to the recipient, but also the conditions that make donation ethically and physically sustainable. Donors should contribute surplus rather than milk their own infant needs. They need support that prevents excessive donation and protects lactation. A donor who does not qualify should not be left with the impression that their milk is unsafe for their own infant. A bank that collects more milk by harming those relationships has not improved the product pathway, even if its storage room is full.

The starting material is variable. Lactation stage, gestational age and maternal factors shape composition before any treatment begins. Pooling can reduce variation in protein and fat and may make the administered product more consistent, but it can also hide differences that might matter biologically and increase the amount lost when one contribution compromises a batch. This means that a post-treatment difference cannot automatically be assigned to the treatment. It may reflect the donor mix, storage history, pooling decision and process together.

Safety is distributed across the same pathway. Screening addresses risks associated with the donor and exposures that may enter the milk. Hygienic expression and appropriate containers reduce avoidable contamination at collection. Cold-chain control limits growth during storage and transport. Pooling and labeling determine how a batch is identified and how much milk shares a common failure risk. Treatment reduces many microbial hazards. Post-treatment testing checks a defined safety property before release. Track-and-trace makes an adverse event investigable.

A treatment cannot repair every earlier failure, and a favorable microbial result cannot prove that the milk’s biology is unchanged. The product that reaches a recipient is the result of all of these transitions. The quality question is therefore multidimensional: is the milk safe enough against the relevant hazard, does it retain important biological properties, has a meaningful clinical benefit been demonstrated, and can the bank deliver it without reducing equitable access?

Holder pasteurization makes the tension visible. Heating donor milk to 62.5 °C for 30 minutes can reduce many bacterial and viral hazards, and WHO treats Holder pasteurization or HTST as the general balance of safety and quality for milk from screened healthy women. But heat treatment is not sterilization. Bacillus spores are not destroyed by heat, and lower heat exposure did not consistently inactivate viruses in the evidence reviewed by WHO. The process also changes selected heat-sensitive vitamins, immune proteins and enzymes.

The molecular evidence makes the word “change” more precise.